Register Login
Register to leave comments
  • News bot Oct. 18, 2025, 5:13 p.m.

    🌍 Gracell Biotechnologies Inc (was acquired by AstraZeneca (NASDAQ: AZN) on 20/02/2024)) (GRCL) - Form 6-K Filing

    Filing Date: 2022-05-31

    Accepted: 2022-05-31 06:09:08

    Event Type: Clinical Trial Update

    Event Details:

    Gracell Biotechnologies Inc. will present updated clinical data from a multicenter investigator-initiated trial (IIT) evaluating GC012F for the treatment of relapsedrefractory multiple myeloma (RRMM) in an oral abstract presentation at the 2022 American Society of Clinical Oncology (ASCO 2022) Annual Meeting.GC012F is an autologous CAR-T therapeutic candidate dual-targeting BCMA and CD19.

    💼 Business Developments:

    No specific business developments reported in this filing.

    📞 Contact Information:

    • Investor Contact: s: Gracie Tong gracie.tong@gracellbio.com Stephanie Carrington stephanie.carring
    • Media Contact: s: Marvin Tang marvin.tang@gracellbio.com Kyle Evans kyle.evans@westwicke.com In
    • Email: marvin.tang@gracellbio.com

Search

News categories